PharmaTimesNews & Politicsnews

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity

Thursday, June 4, 2026John PinchingView original

Late‑breaking EULAR results highlight sustained responses through week 52

Read the full article on the original site.

Read Full Article